ReviewDrug discovery today2019
The human endogenous metabolome as a pharmacology baseline for drug discovery.
Review in Drug discovery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Identification of indoles as potential endogenous ligands of ERRγ and their modulation on drug binding.Acta pharmacologica Sinica · 2025Article
- Analysis of metabolites in human gut: illuminating the design of gut-targeted drugs.Journal of cheminformatics · 2023Article
- Data-driven analysis and druggability assessment methods to accelerate the identification of novel cancer targets.Computational and structural biotechnology journal · 2023Review
- Role of Pyroptosis in Intervertebral Disc Degeneration and Its Therapeutic Implications.Biomolecules · 2022Review
- The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes.Molecules (Basel, Switzerland) · 2021Review
- A New Metric Quantifying Chemical and Biological Property of Small Molecule Metabolites and Drugs.Frontiers in molecular biosciences · 2020Article
- Applying the human metabolome.Nature reviews. Drug discovery · 2019Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
We have limited understanding of the variation in in vitro affinities of drugs for their targets. An analysis of a highly curated set of 815 interactions between 566 drugs and 129 primary targets reveals that 71% of drug-target affinities have values above that of the corresponding endogenous ligand, 96% of them fitting within a range of two orders of magnitude. Our findings suggest that the evolutionary optimised affinity of endogenous ligands for their native proteins can serve as a baseline for the primary pharmacology of drugs. We show that the degree of off-target selectivity and safety risks of drugs derived from their secondary pharmacology depend very much on that baseline. Thus, we propose a new approach for estimating safety margins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.